Ovarian cancer is a leading cause of death among gynecological malignancies. Established cancer cell lines are useful tools for clinical and basic researches. We have therefore established a new human ovarian cancer cell line, YDOV-151, derived from the mucinous cystadenocarcinoma and characterized it by the microarray analyses. A mucinous origin of the YDOV-151 was evident from light microscopy, and its epithelial-like character was confirmed with electron microscopy. No pathogenic mutations were found in the BRCA1 and BRCA2 genes. The subcutaneous transplantation of YDOV-151 cells into nude mice successfully induced the tumor mass after 3 weeks. cDNA microarray analysis revealed 1,926 genes (> 2-fold differences, P < 0.05) that distinguished the YDOV-151 from human ovarian surface epithelial (HOSE) cells. To identify candidate biomarkers, we selected five genes (SFN, RGC32, CDCA7, LAMP3, and SLCO4A1), each of which was up-regulated (> 7-fold) in YDOV-151 and had an available antibody assay for further validation. In SYBR Green real-time PCR, the relative expression levels of RGC32 (651-fold), LAMP3 (1,930-fold), and SLCO4A1 (20,598-fold) were significantly higher in YDOV-151 than in HOSEs (P < 0.001). RGC32 may be involved in cell cycle regulation, LAMP3 may promote metastasis, and SLCO4A1 is a member of anion-transporting polypeptides. The newly established ovarian cancer cell line, YDOV-151, would be a useful model for elucidating the biology and the pathogenesis of mucinous cystadenocarcinoma. In addition, the identification and validation of up-regulated genes may provide a genetic approach for identifying biomarkers in ovarian cancer.